GLP-1s and sleep apnea: Zepbound's OSA approval

Reviewed 12 sourcesPublished by PepVault

Zepbound is the one drug approved for sleep apnea. The SURMOUNT-OSA results, how fast it works, CPAP, and where semaglutide stands, as of November 2026.

A man in a white tank top with his arms spread wide on a dock by a blue lake
Last reviewed
Sources
12
Questions
8
Compounds
4

The short answer

One drug is approved for sleep apnea: Zepbound (tirzepatide), since December 2024, for moderate to severe obstructive sleep apnea in adults with obesity. In its two 52-week trials, breathing events fell by half or more, 25 to 29 an hour against about 5 on placebo, and 42 to 50% reached remission or mild, symptom-free disease. No semaglutide brand carries this approval. Keeping CPAP is your prescriber's call.

Every number checked at its primary source · · 12 sources · How we research

Evidence: Strong for tirzepatide: two phase 3 randomized, placebo-controlled trials built for sleep apnea (469 adults, 52 weeks). Moderate for liraglutide (one 32-week phase 3 trial) and early for retatrutide (a 243-person subgroup of one phase 3 trial); semaglutide has no dedicated sleep apnea trial published.

A man in a white tank top with his arms spread wide on a dock by a blue lake

Which GLP-1 is approved for sleep apnea?

Only Zepbound. On December 20, 2024, the FDA approved it to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity, alongside a reduced-calorie diet and more physical activity, and called it the first drug treatment option for certain patients with the condition2. The current label, revised August 2026, keeps that indication (the use a drug is approved for) beside its weight-loss one1. Obstructive sleep apnea is breathing that stops or turns shallow again and again during sleep because the throat closes; it is graded by the apnea-hypopnea index (AHI), the number of those events per hour in an overnight sleep study. The label's "moderate to severe" means an AHI of 15 or more, and the trials enrolled people with a BMI of 30 or more1.

Tirzepatide is not a pure GLP-1 drug: it switches on two gut-hormone receptors, GIP and GLP-11. Mounjaro is the same molecule, but its label covers type 2 diabetes and heart risk in diabetes, not sleep apnea12. Wegovy (semaglutide) and Saxenda (liraglutide) are approved for weight, and Wegovy also for heart risk and a fatty-liver disease; neither label names sleep apnea711.

A second kind of drug may follow. In July 2026 the FDA accepted Apnimed's application for AD109, an oral pill that combines aroxybutynin and atomoxetine and works on the throat muscles rather than on weight; the FDA's target date for a decision is February 28, 2027, and until then it stays investigational10.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

Turn on a dose reminder and PepVault nudges you on your weekly shot day, at the time you set, until the dose is logged; each logged dose stays in your history, so every four-week step is easy to see.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What did the SURMOUNT-OSA trials find?

SURMOUNT-OSA was two double-blind trials run side by side, 469 adults in all, with an average BMI of about 39 and an average AHI of about 50, so most had severe disease3. Trial 1 enrolled people not using a breathing machine at night; trial 2 enrolled people already on positive airway pressure (PAP, the CPAP mask and pump). People with type 2 diabetes were left out1. Each person climbed from 2.5 mg to the highest weekly dose they tolerated, 10 or 15 mg, or got a placebo, for 52 weeks3. The table gives the week-52 results, tirzepatide against placebo13.

At week 52Trial 1: no PAPTrial 2: on PAP
Starting AHI, events per hour51.549.5
Change in AHI, events per hour−25.3 vs −5.3−29.3 vs −5.5
Change in AHI, percent−50.7% vs −3.0%−58.7% vs −2.5%
AHI cut by half or more61.2% vs 19.0% of people72.4% vs 23.3%
Remission or mild, symptom-free OSA42.2% vs 15.9%50.2% vs 14.3%
Body weight−17.7% vs −1.6%−19.6% vs −2.3%
Systolic blood pressure (week 48), mm Hg−9.5 vs −1.8−7.6 vs −3.9
Breathing events per hour in SURMOUNT-OSA: trial 1 started at 51.5 and reached 26.2 on tirzepatide against 46.2 on placebo; trial 2 started at 49.5 and reached 20.2 against 44.0, over bands for under 5, 5 to 14, and 15 or more (moderate to severe)
Where the average person started and ended in SURMOUNT-OSA: from severe to the edge of moderate on tirzepatide.

"Remission or mild, symptom-free" is the label's own phrase for an AHI under 5, or an AHI of 5 to 14 with an Epworth sleepiness score of 10 or less (a daytime-sleepiness questionnaire scored 0 to 24)1. The trials' authors note that at those levels a PAP machine may no longer be recommended3. People in trial 2 stopped their machine for 7 days before each sleep study, so its numbers show breathing without the mask3. Tirzepatide also lowered the oxygen dips during the night, a marker of inflammation (hsCRP), and how impaired and disturbed people rated their sleep3.

How does a weight-loss drug ease sleep apnea?

Mostly through the weight it takes off. Excess body fat is a major risk factor for obstructive sleep apnea, and one that can be reversed3, and the FDA wrote that Zepbound's improvement in AHI is likely related to the weight lost2. A later analysis of both trials found that the people who lost more weight had larger drops in AHI and in the night's oxygen dips4. The working picture is that less fat around the neck and airway leaves the throat less likely to fall shut when the muscles relax in sleep; a 2026 review calls that the most likely explanation, while noting it has not yet been confirmed by imaging the airway of people on these drugs8.

Whether tirzepatide does anything for breathing beyond the weight is still open: the authors of that analysis say more research is needed to separate the two4.

How fast does Zepbound work for sleep apnea?

Over months, not nights. CPAP holds the airway open from the first night; a drug works as weight comes off. The label's climb starts at 2.5 mg a week for four weeks and steps up 2.5 mg at a time, at least four weeks apart, to a maintenance dose of 10 or 15 mg for sleep apnea, with 15 mg the maximum1. In the trials that climb took up to 20 weeks3. These are the label's and the trials' schedules, not a dose for any one person.

Weeks 0 to 52 of SURMOUNT-OSA: the dose climb from 2.5 mg to 10 or 15 mg over up to 20 weeks; a home device showed breathing events falling from each person’s start by week 4, the gap against placebo clear by week 20, and the full result at week 52
The dose climb ends by week 20, the same week the gap against placebo became clear.

In trial 1, a home sleep device showed AHI falling from each person's own starting point as early as week 4, but the gap against placebo was not clear until week 204. The full result was measured at week 523. That analysis was planned after the main results (a post hoc analysis), so it describes the timing rather than proving it.

Turn on a dose reminder and PepVault nudges you on your weekly shot day, at the time you set, until the dose is logged; each logged dose stays in your history, so every four-week step is easy to see. Set reminders in PepVault

Does Zepbound replace CPAP?

Not on the label. Its words are plain: the sleep apnea trials did not evaluate the timing or appropriateness of stopping PAP in people who were using it well1. What the trials do show is that the drug worked with or without a machine: in PAP users, measured with the mask off, 50.2% reached remission or mild disease, against 42.2% in people not using one (two separate trials, not compared with each other)13. Even so, about half of the people on tirzepatide in trial 2, and more than half in trial 1, did not reach that level1.

So the drug and the machine answer different needs: the machine treats every night it is worn, and the drug works on the weight that narrows the airway. Whether to treat sleep apnea with a drug, and whether to keep the CPAP once breathing improves, is a decision for you and your prescriber or sleep clinic, usually after a repeat sleep study.

When to get help Dozing off while driving, or a partner noticing long pauses in your breathing again, is a reason to call your sleep clinic soon.

What about semaglutide, liraglutide and retatrutide?

Other drugs in the family have sleep apnea data, but none has the approval. Semaglutide (Wegovy, Ozempic) has no published randomized trial built for sleep apnea; a 2026 review of the evidence names liraglutide and tirzepatide as the only drugs in the class with direct sleep apnea trials, and calls semaglutide's data indirect, from its obesity trials8. The table puts the trials that do exist side by side.

DrugTrialChange in AHI, events per hourWeightApproved for OSA?
Tirzepatide (Zepbound)SURMOUNT-OSA, 469 adults, 52 weeks3−25.3 and −29.3 vs about −5 on placebo−17.7% and −19.6%Yes, December 20242
Liraglutide 3.0 mg (Saxenda)SCALE Sleep Apnea, 359 adults, 32 weeks5−12.2 vs −6.1−5.7% vs −1.6%No11
Retatrutide 4, 9 and 12 mgTRIUMPH-1 subgroup, 243 adults, 80 weeks6−22.9, −34.3 and −31.7 vs −9.9Whole trial: −17.6%, −23.7% and −25.0% vs −3.9%No: not an approved drug
Semaglutide (Wegovy)No dedicated sleep apnea trial published8——No7
A scatter of weight lost against the change in breathing events per hour: liraglutide −5.7% and −12.2; tirzepatide −17.7% and −25.3, −19.6% and −29.3; retatrutide 4, 9 and 12 mg −17.6% and −22.9, −23.7% and −34.3, −25.0% and −31.7
More weight lost, fewer breathing events: the pattern across the three drugs with sleep apnea data.

The pattern follows weight. Liraglutide took off about 6% and cut AHI by about 6 events an hour more than placebo; in its trial, too, more weight lost went with more improvement5. Retatrutide, a Lilly drug that adds a third receptor, glucagon, had larger AHI drops than tirzepatide's at its 9 and 12 mg doses, but over 80 weeks rather than 52 and in a different trial with a larger placebo drop, and no trial has compared them head to head. It is not an approved drug, and its sleep apnea result comes from 243 people inside a larger weight trial, which is weaker evidence than a trial built for sleep apnea6.

What side effects came up in the sleep apnea trials?

The same stomach effects as in the weight trials, mostly mild to moderate and mostly during the dose climb3. The label states that the side effects in the sleep apnea trials were similar to those in the weight-loss trials1. On tirzepatide, against placebo, in trial 1 and trial 23:

  • Diarrhea: 26.3% and 21.8%, against 12.5% and 8.8%.
  • Nausea: 25.4% and 21.8%, against 10.0% and 5.3%.
  • Vomiting: 17.5% and 9.2%, against 4.2% and 0.9%.
  • Constipation: 15.8% and 15.1%, against 2.5% and 4.4%.
  • Stopped because of a side effect: 4.4% and 3.4%, against 1.7% and 7.0%.

What helps in the step-up weeks is ordinary: smaller meals, eating slowly and stopping at the first sign of fullness. The full list of side effects and warnings is on the tirzepatide side effects page and in the label1.

Commonly reported: in users' own accounts, not trial measures, quieter nights and less snoring as the weight comes off, waking more rested within a few months, and nausea or fullness for a day or two after each dose step.

What happens to sleep apnea if you stop Zepbound?

No trial has measured it yet. SURMOUNT-OSA treated people for 52 weeks and did not follow their breathing after the drug stopped3. What is known is what happens to the weight, which the trials tied to the breathing. In SURMOUNT-4, a weight trial rather than a sleep apnea one, people who lost 20.9% over 36 weeks on tirzepatide and were then switched to placebo regained 14.0% of their body weight over the next year, while those who stayed on it lost another 5.5%9. If the airway improvement rides on the weight, it is a fair guess, not a measured result, that it slips as the weight returns; a repeat sleep study is how you would know.

PepVault keeps your weigh-ins on one chart and your doses in the log, so the weight change the trials tied to fewer breathing events is ready for your next sleep or weight visit. Track your weight in PepVault

Track it in the app

Sources

  1. Zepbound (tirzepatide) injection, prescribing information. Eli Lilly and Company. DailyMed, revised August 2026 (SPL version 40). dailymed.nlm.nih.gov
  2. U.S. Food and Drug Administration. FDA approves first medication for obstructive sleep apnea. Press announcement, December 20, 2024. fda.gov
  3. Malhotra A et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193-1205. PubMed 38912654
  4. Malhotra A et al. Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: time course and association with body weight. Sleep Med. 2025;136:106853. PubMed 41135142
  5. Blackman A et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016;40(8):1310-1319. PubMed 27005405
  6. Jastreboff AM et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1). N Engl J Med. 2026;395(18):1781-1793. PubMed 42814954
  7. Wegovy (semaglutide) injection and tablets, prescribing information. Novo Nordisk. DailyMed, published June 30, 2026. dailymed.nlm.nih.gov
  8. Zhang X et al. Incretin-based therapies in obesity-related obstructive sleep apnea: a narrative review of evidence tiers and mechanistic plausibility. Nat Sci Sleep. 2026;18:611573. PubMed 42591103
  9. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. PubMed 38078870
  10. Apnimed. Apnimed announces FDA acceptance of New Drug Application for AD109, an investigational oral pill to treat adults with obstructive sleep apnea. Press release, July 14, 2026. prnewswire.com
  11. Saxenda (liraglutide) injection, prescribing information. Novo Nordisk. DailyMed. dailymed.nlm.nih.gov
  12. Mounjaro (tirzepatide) injection, prescribing information. Eli Lilly and Company. DailyMed. dailymed.nlm.nih.gov

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo